Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2018

View Archived Issues

Early safety and efficacy data support use of MAGE-A4 SPEAR T cells for treatment of solid tumors

Targeting LILRB4 may augment immunotherapy in leukemia

First mouse model of Costello syndrome highlights role of altered metabolism in disease

A 20p11.2 deletion including FOXA2 causes hyperinsulinemic hypoglycemia

ZMYM2 -- a new candidate gene for congenital anomalies of the kidney and urinary tract

Acute kidney injury prevented in mice by prophylactic treatment with DNase I inhibitor

Obesity drives NASH, liver cancer via distinct mechanisms

Durable tumor responses reported for ODM-203 in phase I/II KIDES trial

Drugging "undruggable" zinc fingers

Clean antagonist antibody can control skin inflammation

BAY-1161909 in combination with paclitaxel demonstrates antitumor efficacy but trial terminated

Preliminary phase I results of ABBV-181 reported at ESMO

Limited antitumor efficacy and high rates of hypertension in breast cancer with lucitanib

AbbVie patents new BRD4 inhibitors

Zion Medical reports first clinical data for HIV drug Gammora

FDA approves pegfilgrastim biosimilar Udenyca

Cancer Research Technology identifies RET inhibitors

Phase III study of Venclexta with Gazyva in treatment-naive CLL meets primary endpoint

European Commission approves Symkevi in cystic fibrosis

FDA approves adalimumab biosimilar Hyrimoz

Interim phase I results reported for ISC-hpNSC cell therapy in Parkinson's disease patients

FDA issues complete response letter for oliceridine NDA

SanBio's phase II trial of SB-623 in traumatic brain injury meets primary endpoint

FDA approves Lorbrena for previously treated ALK-positive metastatic NSCLC

Leo Pharma opens phase Ib study of LEO-134310 in chronic plaque psoriasis

FDA approves Dsuvia for acute pain in healthcare settings

Recombinant Lassa-rabies virus vaccine LASSARAB protects guinea pigs from Lassa fever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...